Could This Covid Anti Viral Pill Fuel The Emergence Of New Variants
The anti-viral pill molnupiravir, developed by Merck and Ridgeback Biotherapeutics, was authorized for emergency use in the United States by the Food and Drug Administration (FDA) on December 23, 2021, after an advisory panel narrowly endorsed the medication. The pill is designed to treat adults with mild-to-moderate COVID-19 symptoms who are at high risk of severe disease. Molnupiravir is available by prescription only and should be initiated as soon as possible after a COVID-19 diagnosis and within five days of symptom onset....